Services
Genomic testing & Drug & Equipment
Prostate Cancer
Kidney Cancer
Urothelial Cancer
Lung Cancer
Colorectal Cancer
Breast Cancer
Head And Neck
Other Diseases
Detection Process
Shenshian™ selected
It is currently the most comprehensive genetic hereditary kidney cancer product, covering guideline recommendations, family evidence, genetic susceptibility, ESMO precision medicine working group recommendations, renal tumor-related, and kidney cancer germline high-frequency genes.
GloriousMed has passed the CAP authoritative certification and complies with the IS015189 international quality system standard. The sensitivity and specificity of the detection are greater than 99%.
With the latest kidney cancer gene knowledge base and a large amount of kidney cancer gene data,the report interpretation is more professional and suitable for clinical treatment.
GloriousMed has published four kidney cancer-related articles a year, respectively on TFE3-fusion RCC, FH-RCC, and renal clear cell carcinoma with sarcomatoid multiple metastases, among which TFE3-fusion RCC related content has been published in Nature Communications.
It can evaluate prognosis, targeted drugs and immune drug efficacy.
It can comprehensively indicate the risk of hereditary kidney cancer and other hereditary tumor.
Stage IV non-ccRCC patientsNon-ccRCC patients with tumor recurrence or metastasisSuspected population of hereditary kidney cancer (family history, ≤45 years old, double and multifocal)Stage IV ccRCC patients with second-line and last-line therapyccRCC patients with tumor recurrence or metastasisShenshian™
It is currently the most comprehensive genetic hereditary kidney cancer product, covering guideline recommendations, family evidence, genetic susceptibility, ESMO precision medicine working group recommendations, renal tumor-related, and kidney cancer germline high-frequency genes.
GloriousMed has passed the CAP authoritative certification and complies with the IS015189 international quality system standard. The sensitivity and specificity of the detection are greater than 99%.
With the latest kidney cancer gene knowledge base and a large amount of kidney cancer gene data,the report interpretation is more professional and suitable for clinical treatment.
GloriousMed has published four kidney cancer-related articles a year, respectively on TFE3-fusion RCC, FH-RCC, and renal clear cell carcinoma with sarcomatoid multiple metastases, among which TFE3-fusion RCC related content has been published in Nature Communications.
It can evaluate prognosis, targeted drugs and immune drug efficacy.
It can comprehensively indicate the risk of hereditary kidney cancer and other hereditary tumor.
Stage IV non-ccRCC patientsNon-ccRCC patients with tumor recurrence or metastasisSuspected population of hereditary kidney cancer (family history, ≤45 years old, double and multifocal)Stage IV ccRCC patients with second-line and last-line therapyccRCC patients with tumor recurrence or metastasisShenshian™ plus
It is currently the most comprehensive genetic hereditary kidney cancer product, covering guideline recommendations, family evidence, genetic susceptibility, ESMO precision medicine working group recommendations, renal tumor-related, and kidney cancer germline high-frequency genes.
GloriousMed has passed the CAP authoritative certification and complies with the IS015189 international quality system standard. The sensitivity and specificity of the detection are greater than 99%.
With the latest kidney cancer gene knowledge base and a large amount of kidney cancer gene data,the report interpretation is more professional and suitable for clinical treatment.
GloriousMed has published four kidney cancer-related articles a year, respectively on TFE3-fusion RCC, FH-RCC, and renal clear cell carcinoma with sarcomatoid multiple metastases, among which TFE3-fusion RCC related content has been published in Nature Communications.
It can evaluate prognosis, targeted drugs and immune drug efficacy.
It can comprehensively indicate the risk of hereditary kidney cancer and other hereditary tumor.
Stage IV non-ccRCC patientsNon-ccRCC patients with tumor recurrence or metastasisSuspected population of hereditary kidney cancer (family history, ≤45 years old, double and multifocal)Stage IV ccRCC patients with second-line and last-line therapyccRCC patients with tumor recurrence or metastasisShenshian™detects
It is currently the most comprehensive genetic hereditary kidney cancer product, covering guideline recommendations, family evidence, genetic susceptibility, ESMO precision medicine working group recommendations, renal tumor-related, and kidney cancer germline high-frequency genes.
GloriousMed has passed the CAP authoritative certification and complies with the IS015189 international quality system standard. The sensitivity and specificity of the detection are greater than 100%.
With the latest kidney cancer gene knowledge base and a large amount of kidney cancer gene data,the report interpretation is more professional and suitable for clinical treatment.
GloriousMed has published four kidney cancer-related articles a year, respectively on TFE3-fusion RCC, FH-RCC, and renal clear cell carcinoma with sarcomatoid multiple metastases, among which TFE4-fusion RCC related content has been published in Nature Communications.
It can comprehensively indicate the risk of hereditary kidney cancer and other hereditary tumor.
Kidney cancer patients aged ≤45 yearsBilateral/Multiple Kidney TumorsFamily history of kidney cancerHistory of kidney cancer with other tumorsKidney cancer with rare skin lesions
400-696-6908Contact Information
info@gloriousmed.comEmail
No. 11, Lane 100, Banxia Road, Pudong New Area, ShanghaiCompany address
Follow us to learn moreWeChat public account
PROSTATE CANCER 
